Novavax ( NASDAQ: NVAX) was on track to end its seventh consecutive session in the red territory after shares of the company declined 1.73% to $6.54 on Friday afternoon. The vaccine maker lost close ...

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine ...

Check out our earnings calendar for this week, as well as our previews and recaps of the more noteworthy reports.

In the most recent trading session, Novavax (NVAX) closed at $6.85, indicating a -2.28% shift from the previous trading day.

The threat of another influenza pandemic arising from bird-to-human and then human-to-human transmission drives continuing efforts to develop effective vaccines against avian influenza. In the latest ...

Shares of Novavax Inc. NVAX slid 2.28% to $6.85 Wednesday, on what proved to be an all-around mixed trading session for the ...

Vinay Prasad, who headed the U.S. FDA division in charge of vaccines and was also chief medical and scientific officer, has ...

HHS Secretary RFK Jr. vows to reform the Vaccine Injury Program, highlighting inefficiencies and favoritism in compensating ...

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.